Low levels of ATM in breast cancer patients with clinical radiosensitivity
Date
2010-06-24
Authors
Fang, Zhiming
Kozlov, Sergei
McKay, Michael J
Woods, Rick
Birrell, Geoff
Sprung, Carl N
Murrell, Dédée F
Wangoo, Kiran
Teng, Linda
Kearsley, John H
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
Abstract
BACKGROUND AND PURPOSE Adjuvant radiotherapy for cancer can result in severe adverse side effects for normal tissues. In this respect, individuals with anomalies of the ATM (ataxia telangiectasia) protein/gene are of particular interest as they may be at risk of both breast cancer and clinical radiosensitivity. The association of specific ATM gene mutations with these pathologies has been well documented, however, there is uncertainty regarding pathological thresholds for the ATM protein. RESULTS Semi-quantitative immuno-blotting provided a reliable and reproducible method to compare levels of the ATM protein for a rare cohort of 20 cancer patients selected on the basis of their severe adverse normal tissue reactions to radiotherapy. We found that 4/12 (33%) of the breast cancer patients with severe adverse normal tissue reactions following radiotherapy had ATM protein levels < 55% compared to the mean for non-reactor controls. CONCLUSIONS ATM mutations are generally considered low risk alleles for breast cancer and clinical radiosensitivity. From results reported here we propose a tentative ATM protein threshold of ~55% for high-risk of clinical radiosensitivity for breast cancer patients.
Description
Keywords
Keywords: ATM protein; adult; aged; article; blood sampling; breast cancer; breast fibrosis; cancer patient; cancer risk; chromosome aberration; clinical article; controlled study; cystitis; desquamation; enzyme activity; female; gene mutation; genetic association;
Citation
Collections
Source
Genome Integrity
Type
Journal article
Book Title
Entity type
Access Statement
License Rights
Restricted until
Downloads
File
Description
Published Version